At the time of writing, Travere Therapeutics Inc [TVTX] stock is trading at $19.57, up 4.04%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The TVTX shares have gain 7.23% over the last week, with a monthly amount glided 11.83%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Travere Therapeutics Inc [NASDAQ: TVTX] stock has seen the most recent analyst activity on October 21, 2024, when Wells Fargo upgraded its rating to a Overweight and also boosted its price target to $27 from $9. On September 09, 2024, upgrade upgraded it’s rating to Buy but maintained its price target of $25 on the stock. Guggenheim downgraded its rating to a Neutral. Citigroup upgraded its rating to a Buy and raised its price target to $10 on December 05, 2023. Citigroup started tracking with a Neutral rating for this stock on November 20, 2023, and assigned it a price target of $7. In a note dated September 22, 2023, Wells Fargo downgraded an Equal Weight rating on this stock and revised its target price from $24 to $8.
For the past year, the stock price of Travere Therapeutics Inc fluctuated between $5.12 and $20.33. Currently, Wall Street analysts expect the stock to reach $21.75 within the next 12 months. Travere Therapeutics Inc [NASDAQ: TVTX] shares were valued at $19.57 at the most recent close of the market. An investor can expect a potential return of 11.14% based on the average TVTX price forecast.
Analyzing the TVTX fundamentals
According to Travere Therapeutics Inc [NASDAQ:TVTX], the company’s sales were 203.45M for trailing twelve months, which represents an 69.56% jump. Gross Profit Margin for this corporation currently stands at 0.84% with Operating Profit Margin at -1.69%, Pretax Profit Margin comes in at -1.71%, and Net Profit Margin reading is -1.73%. To continue investigating profitability, this company’s Return on Assets is posted at -0.7, Equity is -5.42 and Total Capital is -1.09. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -12.6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 19.00 points at the first support level, and at 18.44 for the second support level. However, for the 1st resistance point, the stock is sitting at 19.99, and for the 2nd resistance point, it is at 20.42.
Ratios To Look Out For
It is important to note that Travere Therapeutics Inc [NASDAQ:TVTX] has a current ratio of 1.71. As well, the Quick Ratio is 1.68, while the Cash Ratio is 0.19. Considering the valuation of this stock, the price to sales ratio is 8.42.
Transactions by insiders
Recent insider trading involved Calvin Sandra, SVP, CHIEF ACCOUNTING OFFICER, that happened on Nov 25 ’24 when 12090.0 shares were sold. Officer, Calvin Sandra completed a deal on Nov 25 ’24 to buy 12090.0 shares. Meanwhile, Director LYONS GARY A sold 40000.0 shares on Oct 04 ’24.
